PriceTargets.com logo

Spectrum Pharmaceuticals - SPPI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.03 As of 08/1/2023 01:00 AM ET
+0 (0.00%)
Get New Spectrum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPPI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Spectrum Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.03.

This chart shows the closing price for SPPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Spectrum Pharmaceuticals. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/15/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
4/26/2023HC WainwrightDowngradeBuy ➝ Neutral
4/26/2023JMP SecuritiesDowngradeOutperform ➝ Market Perform
2/3/2023Cantor FitzgeraldLower TargetNeutral$3.00 ➝ $0.75
2/1/2023JMP SecuritiesReiterated RatingMarket Outperform$4.00
1/31/2023HC WainwrightReiterated RatingBuy$4.00
11/25/2022HC WainwrightLower TargetBuy$6.00 ➝ $4.00
11/16/2022B. RileyDowngradeBuy ➝ Neutral$1.50 ➝ $1.00
9/23/2022JMP SecuritiesReiterated RatingBuy$4.00
9/23/2022B. RileyLower Target$4.00 ➝ $1.50
9/20/2022HC WainwrightLower TargetBuy$12.00 ➝ $9.00
9/12/2022HC WainwrightBoost TargetBuy$10.00 ➝ $12.00
6/8/2022Cantor FitzgeraldReiterated RatingNeutral
6/7/2022JMP SecuritiesReiterated RatingBuy$4.00
5/27/2022HC WainwrightReiterated RatingBuy$10.00
4/13/2022JMP SecuritiesReiterated RatingBuy$4.00
4/1/2022Cantor FitzgeraldReiterated RatingNeutral
3/21/2022JMP SecuritiesReiterated RatingBuy$4.00
3/21/2022B. RileyLower TargetBuy$6.00 ➝ $4.00
3/8/2022JMP SecuritiesReiterated RatingBuy$4.00
11/12/2021B. RileyReiterated RatingBuy
9/20/2021JMP SecuritiesReiterated RatingBuy$4.00
8/18/2021B. RileyLower TargetBuy$8.00 ➝ $6.00
4/12/2021B. RileyReiterated RatingBuy$8.00
10/26/2020HC WainwrightLower TargetBuy$13.00 ➝ $12.00
9/17/2020JMP SecuritiesInitiated CoverageOutperform$12.00
8/11/2020HC WainwrightReiterated RatingBuy$13.00
8/3/2020HC WainwrightBoost TargetBuy$11.00 ➝ $13.00
7/28/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$4.00 ➝ $7.00
7/2/2020B. RileyReiterated RatingBuy$8.00
6/22/2020B. RileyReiterated RatingBuy$8.00
3/2/2020B. RileyLower TargetBuy$11.00 ➝ $8.00
12/27/2019B. RileyLower TargetBuy$18.00 ➝ $11.00
12/26/2019GuggenheimDowngradeBuy ➝ Neutral
12/26/2019HC WainwrightInitiated CoverageBuy$41.00 ➝ $11.00
12/26/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$17.00 ➝ $4.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.03
Low: $1.03
High: $1.03

50 Day Range

MA: $1.01
Low: $0.94
High: $1.03

52 Week Range

Now: $1.03
Low: $0.32
High: $1.57

Volume

N/A

Average Volume

1,927,028 shs

Market Capitalization

$211.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Spectrum Pharmaceuticals?

The following equities research analysts have issued reports on Spectrum Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for SPPI.

What is the current price target for Spectrum Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Spectrum Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Spectrum Pharmaceuticals in the next year.
View the latest price targets for SPPI.

What is the current consensus analyst rating for Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SPPI.

What other companies compete with Spectrum Pharmaceuticals?

Other companies that are similar to Spectrum Pharmaceuticals include Ironwood Pharmaceuticals, Sangamo Therapeutics, Emergent BioSolutions, Codexis and Rigel Pharmaceuticals. Learn More about companies similar to Spectrum Pharmaceuticals.

How do I contact Spectrum Pharmaceuticals' investor relations team?

Spectrum Pharmaceuticals' physical mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company's listed phone number is (617) 586-3900 and its investor relations email address is [email protected]. The official website for Spectrum Pharmaceuticals is www.sppirx.com. Learn More about contacing Spectrum Pharmaceuticals investor relations.